Zala Megyei Szent Rafael Korhaz
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Zala Megyei Szent Rafael Korhaz, cardiovascular research focuses on cardiovascular disease, primary prevention of atherosclerotic cardiovascular disease, and acute myocardial infarction. These studies are designed to evaluate new ways to reduce heart-related risk, improve prevention, and support recovery after major cardiac events.
- Testing therapies aimed at lowering the risk of major cardiovascular events
- Studying treatment options for patients after a heart attack
- Evaluating approaches for prevention in high-risk individuals
This work highlights a strong interest in improving both long-term cardiovascular protection and immediate care for patients with serious heart disease.
Eye Diseases
Research in eye diseases includes studies of diabetic macular edema, a vision-threatening complication of diabetes. The trials are focused on assessing new treatments that may help protect sight and improve control of retinal swelling.
- Evaluating a new therapy for diabetic eye disease
- Assessing safety and tolerability in patients with retinal complications
- Exploring options that may improve visual outcomes
These studies reflect the site’s involvement in ophthalmic research aimed at preserving vision in people affected by diabetes.
Neoplasms
The oncology program at Zala Megyei Szent Rafael Korhaz is active in neoplasm research, including advanced tumors, extensive stage small cell lung cancer, and ER+/HER2- early breast cancer. The trials are centered on improving cancer treatment effectiveness, reducing recurrence, and extending survival.
- Testing new approaches for advanced and hard-to-treat cancers
- Studying therapies for lung cancer and breast cancer
- Evaluating strategies to prevent cancer return after initial treatment
This area shows a broad oncology focus, with research aimed at both advanced disease control and earlier-stage cancer management.
Nutritional and Metabolic Diseases
Clinical trials in nutritional and metabolic diseases address obesity and type 2 diabetes. The main purpose is to test therapies that can improve blood sugar control, support weight reduction, and lower the health risks linked to metabolic illness.
- Evaluating treatments for better glucose control in type 2 diabetes
- Studying therapies for obesity in people with additional cardiovascular risk
- Exploring ways to improve overall metabolic health
These trials combine diabetes and weight-management research, reflecting the growing need for integrated care in chronic metabolic conditions.
Respiratory Tract Diseases
Research in respiratory tract diseases includes studies of extensive stage small cell lung cancer. The trials are aimed at evaluating whether new treatment strategies can improve survival and support better outcomes in this aggressive cancer.
- Assessing treatment effectiveness in advanced lung cancer
- Studying options that may improve overall survival
- Supporting development of better cancer care for respiratory malignancies
The site’s respiratory research is closely linked with its oncology expertise, especially in difficult-to-treat lung cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 11 therapeutic areas and 15 of 119 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 100 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1AstraZeneca AB6active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB12trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zala Megyei Szent Rafael Korhaz
lock Showing 1 of 59 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 119 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 12 | Unknown | 2018-08-24 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.